Drugs / HEC169584
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07099118 | Sep 2025 → Dec 2026 expected | metabolic dysfunction-associated steatohepatitis | Sunshine Lake Pharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEC169584 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07099118 ↗ |
| Route | Oral | “subjects will take the experiment drug on an empty stomach with 240ml warm water” NCT07099118 ↗ |